Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | EVP and COO | July 16, 2020 | July 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date July 16, 2020 · Filed July 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,000 |
Reported balance
After 2020-07-16 transaction · row 1
1 source rowRow 1 · 2020-07-16 · Purchase · Acquired 5,000 · Balance 55,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2020 Filed Jul 16, 2020 21:10 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 5,000 | $12.95 | $64,740.00 |
DisclosureSEC source: 0001104659-20-084123 · tm2024951-2_4.xml · nonDerivative · entry 1 Setboun David · CIK 0001807545 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 22:16 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-044272 · tm2014134d6_4.xml · nonDerivative · entry 1 Setboun David · CIK 0001807545 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Shares acquired are shares of restricted stock awarded on April 7, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on the one year anniversary of the date of grant, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.